feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Obesity Pill: Cheaper, Needle-Free Future for UK?

Obesity Pill: Cheaper, Needle-Free Future for UK?

15 Jan

•

Summary

  • UK is reviewing an oral version of the popular GLP-1 obesity drug.
  • A pill could offer a cheaper, needle-free alternative to injections.
  • Experts stress obesity is a chronic disease requiring lifelong management.
Obesity Pill: Cheaper, Needle-Free Future for UK?

A potential breakthrough in obesity treatment is on the horizon for the UK, as the Medicines and Healthcare products Regulatory Agency (MHRA) is currently reviewing a licence application for an oral version of semaglutide. Injectable GLP-1 drugs have seen a surge in popularity, with around 1.6 million adults using them in the past year. However, the high cost of these injections, ranging from £100 to £300, has been a significant barrier for many accessing them privately.

Medical experts are optimistic that the approval of a pill form in the US could lead to a more affordable oral option in the UK. This could pave the way for lifelong management of obesity, similar to treatments for other chronic conditions like high blood pressure or diabetes. For individuals with a fear of needles, this oral medication offers a crucial alternative, removing a significant obstacle to treatment. Experts emphasize that obesity is a chronic disease, not a choice, and managing it lifelong is essential for reducing mortality and preventing severe health complications.

Discussions around cost highlight that a pill version is expected to be cheaper, a critical factor for long-term adherence. Prof Dror Dicker, an obesity specialist, explained that stopping medication often leads to rapid weight regain because the underlying physiological failure persists. He stressed the importance of prioritizing treatment access, citing an analysis from Israel that showed a significant return on investment for the state by treating obesity. The ultimate aim extends beyond weight loss to promoting overall health, supported by numerous studies demonstrating the health benefits of weight reduction.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Experts anticipate the oral version will be cheaper, making lifelong treatment more accessible and affordable for patients managing obesity.
The MHRA is currently reviewing a licence application for oral semaglutide, with a decision to be made following their national assessment procedure.
Yes, experts like Prof Dicker emphasize that obesity is a chronic disease requiring lifelong management, not a lifestyle choice.

Read more news on

Healthside-arrow
trending

Praveen Kumar heads BSF

trending

RSSB Grade 4 result declared

trending

SOF NSO results declared

trending

Seven Dials killer twist

trending

Carrick ends Man United stint

trending

Milan offer for Kostic

trending

Harleen Deol retired out

trending

Hermann, Lawrence win thriller

trending

Helland joins Bologna

You may also like

NHS Faces Flu Treatment Crisis: No Proven Cures

17 Dec, 2025 • 150 reads

article image

Flu Shot: Still Your Best Defense?

14 Dec, 2025 • 163 reads

article image

Christmas Booze Alert: MHRA Warns of Drug Mix Dangers

8 Dec, 2025 • 178 reads

article image

WHO Obesity Guidelines: New Era for Weight-Loss Drugs

5 Dec, 2025 • 217 reads

article image

Holiday Hazards: Food, Jabs, and Fairy Lights!

2 Dec, 2025 • 205 reads

article image